<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC6958466\results\search\testTrace\results.xml">
  <result pre="set of probable peptide vaccine candidates for quick synthesis/production and" exact="testing" post="in the laboratory; and (d) designing of novel therapeutic"/>
  <result pre="and (d) designing of novel therapeutic molecules and their laboratory" exact="testing" post="as well as validation of new drugs or repurposing"/>
  <result pre="and Asia at first. The first major outbreak of ZIKV" exact="infection" post="was reported from the Yap Island in the Federated"/>
  <result pre="was a report of the first three cases of ZIKV" exact="infection" post="in humans in Oyo state, Nigeria [2]. In 1979,"/>
  <result pre="its transmission by an urban vector was found through the" exact="isolation" post="of the virus from A. aegypti mosquitoes in Malaysia"/>
  <result pre="2016, WHO [1] declared that the recent association of Zika" exact="infection" post="with clusters of microcephaly and other neurological disorders constituted"/>
  <result pre="develop too many overt symptoms. Typical symptoms of Zika virus" exact="infection" post="include mild fever, rash, joint/muscle pain, headache, and conjunctivitis."/>
  <result pre="people recover from these symptoms in around a week. ZIKV" exact="infection" post="during pregnancy has been linked to several complications, which"/>
  <result pre="damage in brain, eye damage [20,21]. Another complication of ZIKV" exact="infection" post="is its association with the Guillainâ€&quot;BarrÃ© syndrome (GBS), a"/>
  <result pre="a set of probable vaccine candidates for quick synthesis/production and" exact="testing" post="in the laboratory; (d)Computer-assisted design of novel therapeutics and"/>
  <result pre="testing in the laboratory; (d)Computer-assisted design of novel therapeutics and" exact="testing" post="of new drugs or repurposing already existing FDA-approved drugs."/>
  <result pre="v ( t ) are the time-varying rates of mosquito-to-human" exact="infection" post="and mosquito birth, respectively, and other parameters are the"/>
  <result pre="structure activity relationship (QSAR) approaches for developing drugs for the" exact="treatment" post="of Zika. These include identifying the novel compounds that"/>
  <result pre="remain in the host bloodstream. In a subsequent naturally acquired" exact="infection" post="by the same pathogen, the memory cells will be"/>
  <result pre="acids, a step is taken toward the corresponding axis, thereby," exact="tracing" post="a graph in its wake that represents the sequence"/>
  <result pre="powerful beyond imagination.â€�Albert Einstein ZIKV is a flavivirus family of" exact="infection" post="transmitted by mosquitos. Because of a series of recent"/>
  <result pre="it became a serious pandemic situation. The concern for the" exact="infection" post="heightened because of babies born from ZIKV infected mothers"/>
  <result pre="any drug nor any vaccine is currently available for the" exact="treatment" post="and prevention of this infection, potential counter measures are"/>
  <result pre="over the past few decades including pharmacophore modeling and virtual" exact="screening" post="of compound databases to identify potential new drugs [87]."/>
  <result pre="the data bank. Thus, both identification of ligand-binding-site for virtual" exact="screening" post="and pharmacophore modeling for discovery of potential anti-Zika drugs"/>
  <result pre="proteins including repurposing of FDA approved drugs [93], high throughput" exact="screening" post="[94], phenotypic screening [95], and computational methods [42,96]. As"/>
  <result pre="of FDA approved drugs [93], high throughput screening [94], phenotypic" exact="screening" post="[95], and computational methods [42,96]. As a result, several"/>
  <result pre="ZIKV drug targets: Viral glycoproteins play important roles for virus" exact="infection" post="and replication processes as it is involved with virus"/>
  <result pre="they are mostly identified using computational methods, mainly through virtual" exact="screening" post="of compound databases, but none are experimentally validated [116]."/>
  <result pre="[111]. Based on this hypothesis, Stephen et al. performed virtual" exact="screening" post="of a database comprising about 20,000 compounds and shortlisted"/>
  <result pre="compound was discarded to other undesirable toxic effects in clinical" exact="testing" post="[99]. Non-nucleoside RNA polymerase inhibitors: By in silico screening"/>
  <result pre="clinical testing [99]. Non-nucleoside RNA polymerase inhibitors: By in silico" exact="screening" post="of a compound library of 100,000 small molecules based"/>
  <result pre="Thus, TPB appears to be a promising compound against ZIKV" exact="infection" post="[130]. Another non-nucleoside inhibitor, emetine was reported to potently"/>
  <result pre="approach for ZIKV drug discovery. As a part of cell-based" exact="screening" post="of 725 FDA-approved drugs, Lovastatin, an HMG-CoA reductase inhibitor"/>
  <result pre="PHA-690509, a cyclin- dependent kinase inhibitor (CDKi), that inhibited ZIKV" exact="infection" post="with an EC50 value of 1.72 mM [94]. Additional"/>
  <result pre="known as roscovitine) and RGB-286147 were found to inhibit ZIKV" exact="infection" post="at sub micro molar concentrations [95]. From these results,"/>
  <result pre="CDK (pfmrk) pharmacophore model [136] could be useful for virtual" exact="screening" post="from a database of antimalarial CDK (pfmrk) inhibitors to"/>
  <result pre="to be a target for discovery of compounds against ZIKV" exact="infection" post="[137]. The inhibitors for the receptor seem to function"/>
  <result pre="is not yet fully understood [141]. It was identified through" exact="screening" post="against ZIKV in SNB-19 cells showing an EC50 value"/>
  <result pre="Incidentally, niclosamide is an FDA-approved drug, mainly used in the" exact="treatment" post="of intestinal helminthiasis and also in pregnancy. However, the"/>
  <result pre="no drug has yet been approved by FDA for the" exact="treatment" post="of ZIKV infection, numerous small molecules have been identified"/>
  <result pre="the aminoquinolines may be used as pharmacophore template for virtual" exact="screening" post="of other databases to identify new potential anti-ZIKV antimalarial"/>
  <result pre="reduce filovirus infections in vitro and in vivo, including DENV" exact="infection" post="[160]. Therefore, these novel host-based targets have the potential"/>
  <result pre="antibodies as therapeutic agents are increasingly becoming important for the" exact="treatment" post="of cancers, infectious diseases, and autoimmune disorders, the approach"/>
  <result pre="rarely in vivo efficacy with clinical data. Therefore, search and" exact="testing" post="for new compounds should continue till a suitable less"/>
  <result pre="and toxicity as well as improve patient adherence [105]. Since" exact="screening" post="for compounds by pharmacophore is essentially a knowledge-based approach,"/>
  <result pre="Therefore, it can serve as a complimentary tool to high-throughput" exact="screening" post="(HTS) for rapid and effective experimental assay from a"/>
  <result pre="gives us the ability to predict the trajectory of an" exact="infection" post="process in a compact manner [167]. In recent years,"/>
  <result pre="SIR model have been explored for the prediction of ZIKV" exact="infection" post="[30,31,32,33,34,35,36]. Besides SIR-type models, public health management in the"/>
  <result pre="and pharmacophore modeling from literature known active compounds and virtual" exact="screening" post="of compound databases. However it is important to note"/>
  <result pre="therapeutics solely from structure-activity relationships of known bioactive compounds, without" exact="testing" post="for efficacies of identified compounds no compound should be"/>
  <result pre="identified compounds no compound should be promoted. First in vitro" exact="testing" post="followed by in vivo if found promising is absolutely"/>
  <result pre="2019) 2.MacNamaraF.N.Zika virus: A report on three cases of human" exact="infection" post="during an epidemic of jaundice in NigeriaTrans. R. Soc."/>
  <result pre="jaundice in NigeriaTrans. R. Soc. Trop. Med. Hyg.19544813914510.1016/0035-9203(54)90006-113157159 3.FagbamiA.H.Zika virus" exact="infection" post="in Nigeria: Virology and seroepidemological investigation in Oyo stateJ."/>
  <result pre="From pathogenesis to disease controlFEMS Microbiol. Lett.2016363fnw20210.1093/femsle/fnw20227549304 16.SutharM.S.DiamondM.S.GaleM.Jr.West Nile virus" exact="infection" post="and immunityNat. Rev. Microbiol.20131111512810.1038/nrmicro295023321534 17.NandyA.DeyS.BasakS.C.Bielinska-WazD.WazP.Characterizing the Zika Virus Genomeâ€&quot;A"/>
  <result pre="September 2019) 22.Cao-LormeauV.M.BlakeA.MonsS.LastereS.RocheC.VanhomwegenJ.DubT.BaudouinL.TeissierA.LarreP.et al.Guillain-BarrÃ© Syndrome outbreak associated with Zika virus" exact="infection" post="in French Polynesia: A case-control studyLancet20163871531153910.1016/S0140-6736(16)00562-626948433 23.ParraB.LizarazoJ.JorgeA.Jimenez-ArangoJ.A.Zea-VaraA.F.Gonzalez-ManriqueG.VargasJ.AngaritaJ.A.ZunigaG.Lopez-GonzalezR.et al.Guillainâ€&quot;BarrÃ© Syndrome"/>
  <result pre="31.NishiuraH.MizumotoK.Villamil-GomezW.E.Rodriguez-MoralesA.J.Preliminary estimation of the basic reproduction number of Zika virus" exact="infection" post="during Colombia epidemic, 2015â€&quot;2016Trav. Med. Infect. Dis.20161427427610.1016/j.tmaid.2016.03.01627060613 32.MlakarJ.KorvaM.TulN.PopovicM.Poljsak-PriteljM.MrazJ.KolencJ.RusK.R.VipotnikT.V.VodusekV.F.et al.Zika"/>
  <result pre="data sparsity to identify potential sources of Zika virus spillover" exact="infection" post="among primatesEpidemics201927596510.1016/j.epidem.2019.01.00530902616 38.SahooM.JenaL.DafS.KumarS.Virtual Screening for Potential Inhibitors of NS3"/>
  <result pre="Host Microbe20162025927010.1016/j.chom.2016.07.00427476412 94.XuM.LeeE.M.WenZ.ChengY.HuangW.K.QianX.TcwJ.KouznetsovaJ.OgdenS.C.HammackC.et al.Identification of small-molecule inhibitors of Zika virus" exact="infection" post="and induced neural cell death via a drug repurposing"/>
  <result pre="a cell-based, high-throughput screen assayAntivir. Res.2017138475610.1016/j.antiviral.2016.11.01827919709 113.HanY.MesplÃ¨deT.Investigational drugs for the" exact="treatment" post="of Zika virus infection: A preclinical and clinical updateExpert"/>
  <result pre="Inhibiting viral replication and decreasing viral entryCell Discov.2018410.1038/s41421-018-0034-129872540 132.PereraR.RileyC.IsaacG.Hopf-JannaschA.S.MooreR.J.WeitzK.W.Pasa-TolicL.MetzT.O.AdamecJ.KuhnR.J.Dengue virus" exact="infection" post="perturbs lipid homeostasis in infected mosquito cellsPLoS Pathog.2012810.1371/journal.ppat.100258422457619 133.StevensonB.ChoyH.A.PinneM.RotondiM.L.MillerM.C.DemollE.KraiczyP.CooleyA.E.CreamerT.P.SuchardM.A.et"/>
  <result pre="Rep.20171832433310.1016/j.celrep.2016.12.04528076778 138.WangZ.Y.WangZ.ZhenZ.D.FengK.H.GuoJ.GaoN.FanD.Y.HanD.S.WangP.G.AnJ.Axl is not an indispensable factor for zika virus" exact="infection" post="in miceJ. Gen. Virol.2017982061206810.1099/jgv.0.00088628786784 139.BlazquezA.B.Escribano-RomeroE.Merino-RamosT.SaizJ.-C.Martin-AcebesM.A.Stress responses in flavivirus-infected cells:"/>
  <result pre="autophagyFront. Microbiol.201451710.3389/fmicb.2014.0026624478763 140.KuivanenS.BespalovM.M.NandaniaJ.IanevskiA.VelagapudiV.De BrabanderJ.K.KainovD.E.VapalahtiO.Obatoclax, saliphenylhalamide and gemcitabine inhibit Zika virus" exact="infection" post="in vitro and differentially affect cellular signaling, transcription and"/>
  <result pre="virusesFront. Microbiol.20167123310.3389/fmicb.2016.0123327610098 155.LiC.ZhuX.JiX.QuanquinN.DengY.-Q.TianM.AliyariR.ZuoX.YuanL.AfridiS.K.et al.Chloroquine, a FDA-approved drug, prevents Zika Virus" exact="infection" post="and its associated congenital microcephaly in miceEBioMedicine20172418919410.1016/j.ebiom.2017.09.03429033372 156.ShiryaevS.A.MesciP.PintoA.FernandesI.SheetsN.ShrestaS.FarhyC.HuangC.-T.StronginA.Y.MuotriA.R.et al.Repurposing"/>
  <result pre="156.ShiryaevS.A.MesciP.PintoA.FernandesI.SheetsN.ShrestaS.FarhyC.HuangC.-T.StronginA.Y.MuotriA.R.et al.Repurposing of the anti-malaria drug chloroquine for Zika virus" exact="treatment" post="and prophylaxisSci. Rep.201771577110.1038/s41598-017-15467-629150641 157.HanY.MespledeT.XuH.QuanY.WainbergM.A.The antimalarial drug amodiaquine possesses anti-ZIKA"/>
  <result pre="drug amodiaquine possesses anti-ZIKA virus activitiesJ. Med. Virol.20189079680210.1002/jmv.2503129315671 158.ZhouT.TanL.CederquistG.Y.FanY.HartleyB.J.MukherjeeS.TomishimaM.BrennandK.J.ZhangQ.SchwartzR.E.et al.High-content" exact="screening" post="in hPSC-neural progenitors identifies drug candidates that inhibit Zika"/>
  <result pre="in hPSC-neural progenitors identifies drug candidates that inhibit Zika virus" exact="infection" post="in fetal-like organoids and adult brainCell Stem Cell20172127428310.1016/j.stem.2017.06.01728736217 159.CaoB.ParnellL.A.DiamondM.S.MysorekarI.U.Inhibition"/>
  <result pre="2 The pre-epidemics period of the Zika virus after its" exact="detection" post="in 1947. A. africanus: Aedes africanus; ZIKV: Zika virus."/>
  <result pre="africanus; ZIKV: Zika virus. Year Country Remarks 1947 Uganda First" exact="isolation" post="and identification of ZIKV. Found in rhesus monkey, R766,"/>
  <result pre="in children. 1952 Uganda, Tanganyika First human cases of ZIKV" exact="infection" post="detected. India ZIKV antibodies found in human blood. 1953"/>
  <result pre="North Borneo, Philippines ZIKV antibodies found in residents. Nigeria ZIKV" exact="infection" post="detected in three persons. 1954 Egypt, Vietnam ZIKV antibodies"/>
  <result pre="traveler infected in Senegal returning to home country and passing" exact="infection" post="through sexual contact. 2010 Cameroon ZIKV antibodies found in"/>
  <result pre="ZIKV in these countries to travelers who then carried the" exact="infection" post="to their home countries. 2011â€&quot;2014 French Polynesia Second reported"/>
  <result pre="microcephaly and declared a national public health emergency. Brazil reported" exact="detection" post="of ZIKV in amniotic fluid of fetuses with confirmed"/>
  <result pre="an epidemiological alert. 2015 November Mexico Three cases of ZIKV" exact="infection" post="confirmed by PCR. 2015 November French Polynesia Retrospective analysis"/>
  <result pre="infections. 2015 December Puerto Rico First confirmed case of Zika" exact="infection" post="reported. 2016 Maldives Finnish national working in Maldivestested positive"/>
  <result pre="Croix reported. 2016 February Americas First confirmed case of ZIKV" exact="infection" post="in Chile reported.First case of sexually transmitted Zika infection"/>
  <result pre="ZIKV infection in Chile reported.First case of sexually transmitted Zika" exact="infection" post="in Texas, USA reported. 2016 Various countries Angola, Antigua,"/>
  <result pre="countries report first cases of ZIKV infections. 2016 Singapore ZIKV" exact="infection" post="reported. 2016/2017 India Three cases of ZIKV infection reported"/>
  <result pre="Singapore ZIKV infection reported. 2016/2017 India Three cases of ZIKV" exact="infection" post="reported in Ahmedabad. 2017 Singapore Several cases of locally"/>
  <result pre="protein and anti-Toll-like receptor molecules [102] FDA-approved drugs In vitro" exact="screening" post="of 774 compounds led to twenty compounds that were"/>
  <result pre="led to twenty compounds that were found to reduce ZIKV" exact="infection" post="[93] NIH clinical library of compounds By screening 725"/>
  <result pre="reduce ZIKV infection [93] NIH clinical library of compounds By" exact="screening" post="725 chemically diverse compounds from the library, 22 compounds"/>
  <result pre="limited proprietary library of small organic compounds Anti-ZIKV activity through" exact="screening" post="and confirming potent anti-ZIKV activity in in vitro plaque"/>
  <result pre="selective index (SI) values. In a mouse model of ZIKV" exact="infection" post="(300 mg/kg/d), treatment with BCX4430 showed promising results. The"/>
  <result pre="values. In a mouse model of ZIKV infection (300 mg/kg/d)," exact="treatment" post="with BCX4430 showed promising results. The protective effect of"/>
 </snippets>
</snippetsTree>
